CytoDyn Announces Investment Community Call to Discuss Interim Results From Its Treatment Substitution Study in Patients With...
July 30 2014 - 9:51PM
CytoDyn Inc. (OTC.QB:CYDY), a biotechnology
company focused on the development of new therapies for combating
infection with human immunodeficiency virus (HIV), today announced
that the Company will host a live conference call and webcast with
the investment community on Monday, August 4, 2014 at 9:00 a.m. PT
to discuss the interim results from its ongoing Phase 2b treatment
substitution study in patients with HIV.
PRO 140 is a humanized monoclonal antibody directed against
CCR5, a molecular portal that HIV uses to enter cells, and belongs
to a class of HIV therapies known as entry inhibitors that block
HIV from entering into and infecting certain cells.
Conference Call and Webcast Instructions
CytoDyn's management team will host a conference call and live
audio webcast on Monday, August 4, 2014 at 9:00 a.m. PT / 12 noon
ET.
Interested participants and investors may access this conference
call by dialing 877-407-2986 (U.S./Canada) or 201-378-4916
(international).
A live audio webcast may also be accessed via the Investors
section of CytoDyn's corporate web site at www.cytodyn.com, and
will be archived for 30 days. Web participants are encouraged to go
to the web site 15 minutes prior to the start of the call to
register, download and install any necessary software.
A replay of the conference call will be available until
September 3, 2014. To access the replay, interested parties may
dial 877-660-6853 (U.S./Canada) or 201-612-7415 (International);
Conference ID: 13578723.
About PRO 140
PRO 140 belongs to a new class of HIV/AIDS therapeutics --
viral-entry inhibitors -- that are intended to protect healthy
cells from viral infection. PRO 140 is a humanized monoclonal
antibody directed against CCR5, a molecular portal that HIV uses to
enter cells.
PRO 140 has been the subject of four Phase 1/1b and two Phase 2a
clinical trials, each of which demonstrated its ability to
significantly reduce HIV viral load in human test subjects, and has
also been designated a "fast track" product candidate by the
FDA. The PRO 140 antibody appears to be a powerful antiviral
agent leading to potentially fewer side effects and less frequent
dosing requirements as compared to daily drug therapies currently
in use.
About CytoDyn
CytoDyn is a biotechnology company focused on developing
subcutaneously delivered humanized cell-specific monoclonal
antibodies (mAbs) as entry inhibitors for the treatment and
prevention of Human Immunodeficiency Virus (HIV). The Company
has one of the leading mAbs under development for HIV infection,
PRO 140, which is a Late Stage 2 humanized mAb with demonstrated
antiviral activity in man. PRO 140 blocks the HIV co-receptor CCR5
and clinical trial results thus far indicate that it does not
affect the normal function of the cell. Results from Phase
1/1b and Phase 2a human clinical trials have shown that PRO 140 can
significantly reduce viral burden in people infected with
HIV. CytoDyn intends to continue to develop PRO 140 as a
therapeutic anti-viral agent in persons infected with HIV. For more
information on the Company please visit www.cytodyn.com.
Forward-Looking Statements
This press release includes forward-looking statements and
forward-looking information within the meaning of United States
securities laws. These statements and information represent
CytoDyn's intentions, plans, expectations, and beliefs and are
subject to risks, uncertainties and other factors, many beyond
CytoDyn's control. These factors could cause actual results to
differ materially from such forward-looking statements or
information. The words "believe," "estimate," "expect,"
"intend," "attempt," "anticipate," "foresee," "plan," and similar
expressions and variations thereof identify certain of such
forward-looking statements or forward-looking information, which
speak only as of the date on which they are made.
CytoDyn disclaims any intention or obligation to publicly update
or revise any forward-looking statements or forward-looking
information, whether as a result of new information, future events
or otherwise, except as required by applicable law. Readers
are cautioned not to place undue reliance on these forward-looking
statements or forward-looking information. While it is
impossible to identify or predict all such matters, these
differences may result from, among other things, the inherent
uncertainty of the timing and success of and expense associated
with research, development, regulatory approval, and
commercialization of CytoDyn's products and product candidates,
including the risks that clinical trials will not commence or
proceed as planned; products appearing promising in early trials
will not demonstrate efficacy or safety in larger-scale trials;
future clinical trial data on CytoDyn's products and product
candidates will be unfavorable; funding for additional clinical
trials may not be available; CytoDyn's products may not receive
marketing approval from regulators or, if approved, may fail to
gain sufficient market acceptance to justify development and
commercialization costs; competing products currently on the market
or in development may reduce the commercial potential of CytoDyn's
products; CytoDyn, its collaborators or others may identify side
effects after the product is on the market; or efficacy or safety
concerns regarding marketed products, whether or not scientifically
justified, may lead to product recalls, withdrawals of marketing
approval, reformulation of the product, additional pre-clinical
testing or clinical trials, changes in labeling of the product, the
need for additional marketing applications, or other adverse
events.
CytoDyn is also subject to additional risks and uncertainties,
including risks associated with the actions of its corporate,
academic, and other collaborators and government regulatory
agencies; risks from market forces and trends; potential product
liability; intellectual property litigation; environmental and
other risks; and risks that current and pending patent protection
for its products may be invalid, unenforceable, or challenged or
fail to provide adequate market exclusivity. There are also
substantial risks arising out of CytoDyn's need to raise additional
capital to develop its products and satisfy its financial
obligations; the highly regulated nature of its business, including
government cost-containment initiatives and restrictions on
third-party payments for its products; the highly competitive
nature of its industry; and other factors set forth in CytoDyn's
Annual Report on Form 10-K for the fiscal year ended May 31, 2014
and other reports filed with the U.S. Securities and Exchange
Commission.
CONTACT: Investor Relations
Porter, LeVay & Rose, Inc.
Michael J. Porter, President
Office: (212) 546-4700
E-mail: mike@plrinvest.com
CytoDyn (QB) (USOTC:CYDY)
Historical Stock Chart
From Mar 2024 to Apr 2024
CytoDyn (QB) (USOTC:CYDY)
Historical Stock Chart
From Apr 2023 to Apr 2024